Determination of particle heterogeneity and stability of recombinant adenovirus by analytical ultracentrifugation in CsCl gradients

Journal of Pharmaceutical Sciences

Volumn 97, Issue 2, 2008, Pages 746-763

  Yang, Xiaoyu ^a   Agarwala, Shilpi ^a   Ravindran, Sundari ^a   Vellekamp, Gary ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adenoviral vector; Analysis; Analytical ultracentrifugation; Gene therapy; Gene vectors; Heterogeneous systems

Indexed keywords

ADENOVIRUS VECTOR; CESIUM CHLORIDE;

ADENOVIRUS; ADENOVIRUS 5; ARTICLE; DRUG PURIFICATION; GENE THERAPY; MOLECULAR STABILITY; THERMOSTABILITY; ULTRACENTRIFUGATION; VIRUS CAPSID; VIRUS PARTICLE; VIRUS RECOMBINANT;

EID: 39749165316     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21008     Document Type: Article

References (40)

1. Alemany R, Balague C, Curiel DT. 2000. Replicative adenoviruses for cancer therapy. Nat Biotechnol 18:723-727.
2. Vorburger SA, Hunt KK. 2002. Adenoviral gene therapy. Oncologist 7:46-59.
3. Mizuguchi H, Hayakawa T. 2004. Targeted adenovirus vectors. Hum Gene Ther 15:1034-1044.
4. Basak SK, Kiertscher SM, Harui A, Roth MD. 2004. Modifying adenoviral vectors for use as gene-based cancer vaccines. Viral Immunol 17:182-196.
5. Pettersson U, Philipson L, Hoglund S. 1968. Purification and characterization of hexon and fibre antigen from adenovirus type 2. Acta Pathol Microbiol Scand 72:458.
6. Rux JJ, Burnett RM. 2000. Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol Ther 1:18-30.
7. Burlingham BT, Brown DT, Doerfler W. 1974. Incomplete particles of adenovirus. I. Characteristics of the DNA associated with incomplete adeno-virions of types 2 and 12. Virology 60:419-430.
8. Maizel JV Jr, White DO, Scharff MD. 1968. The polypeptides of adenovirus. II. Soluble proteins, cores, top components and the structure of the virion. Virology 36:126-136.
9. Sundquist B, Everitt E, Philipson L, Hoglund S. 1973. Assembly of adenoviruses. J Virol 11:449-459.
10. Prage L, Hoglund S, Philipson L. 1972. Structural proteins of adenoviruses. 8. Characterization of incomplete particles of adenovirus type 3. Virology 49:745-757.
11. Ishibashi M, Maizel JV Jr. 1974. The polypeptides of adenovirus. V. Young virions, structural intermediate between top components and aged virions. Virology 57:409-424.
12. D'Halluin JC, Martin GR, Torpier G, Boulanger PA. 1978. Adenovirus type 2 assembly analyzed by reversible cross-linking of labile intermediates. J Virol 26:357-363.
13. Winberg G, Wadell G. 1977. Structural polypeptides of adenovirus type 16 incomplete particles. J Virol 22:389-401.
14. Vellekamp G, Porter FW, Sutjipto S, Cutler C, Bondoc L, Liu YH, Wylie D, Cannon-Carlson S, Tang JT, Frei A, Voloch M, Zhuang S. 2001. Empty capsids in column-purified recombinant adenovirus preparations. Hum Gene Ther 12:1923-1936.
15. Blanche F, Monegier B, Faucher D, Duchesne M, Audhuy F, Barbot A, Bouvier S, Daude G, Dubois H, Guillemin T, Maton L. 2001. Polypeptide composition of an adenovirus type 5 used in cancer gene therapy. J Chromatogr A 921:39-48.
16. Sutjipto S, Ravindran S, Cornell D, Liu YH, Horn M, Schluep T, Hutchins B, Vellekamp G. 2005. Characterization of empty capsids from a conditionally replicating adenovirus for gene therapy. Hum Gene Ther 16:109-125.
17. Schuck P. 1999. Sedimentation equilibrium analysis of interference optical data by systematic noise decomposition. Anal Biochem 272:199-208.
18. Lebowitz J, Lewis MS, Schuck P. 2002. Modern analytical ultracentrifugation in protein science: A tutorial review. Protein Sci 11:2067-2079.
19. Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt MT, Huang WM, Johnson DE, Anderson SC, Wen SF. 1994. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 5:1079-1088.
20. Perkins TW, Faha B, Ni M, Kiland JA, Poulsen GL, Antelman D, Atencio I, Shinoda J, Sinha D, Brumback L, Maneval D, Kaufman PL, Nickells RW. 2002. Adenovirus-mediated gene therapy using human p21WAF-1/Cip-1 to prevent wound healing in a rabbit model of glaucoma filtration surgery. Arch Ophthalmol 120:941-949.
21. Ling WL, Longley RL, Brassard DL, Armstrong L, Schaefer EJ. 2002. Role of integrin alphaVbeta3 in the production of recombinant adenoviruses in HEK-293 cells. Gene Ther 9:907-914.
22. Ramachandra M, Rahman A, Zou A, Vaillancourt M, Howe JA, Antelman D, Sugarman B, Demers GW, Engler H, Johnson D, Shabram P. 2001. Reengineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol 19:1035-1041.
23. Huyghe BG, Liu X, Sutjipto S, Sugarman BJ, Horn MT, Shepard HM, Scandella CJ, Shabram P. 1995. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther 6:1403-1416.
24. Maizel JV Jr, White DO, Scharff MD. 1968. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2,7A, and 12. Virology 36:115-125.
25. Vellekamp G, Ravindran S, Lin M, Sluzky V, Lehmberg E. 2002. A contaminant in the Adenovirus Reference Material. BioProcessing 1:56-61.
26. Tibbetts C, Giam CZ. 1979. In vitro association of empty adenovirus capsids with double-stranded DNA. J Virol 32:995-1005.
27. Zhu J, Grace M, Casale J, Chang AT, Musco ML, Bordens R, Greenberg R, Schaefer E, Indelicato SR. 1999. Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector. Hum Gene Ther 10:113-121.
28. Colby WW, Shenk T. 1981. Adenovirus type 5 virions can be assembled in vivo in the absence of detectable polypeptide IX. J Virol 39:977-980.
29. Caravokyri C, Leppard KN. 1995. Constitutive episomal expression of polypeptide IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant adenovirus type 5. J Virol 69:6627-6633.
30. Philipson L. 1983. Structure and assembly of adenoviruses. In: Doerfler W, editor. The molecular biology of the adenovirus. NY: Springer-Verlag, pp 1-52.
31. Hasson TB, Ornelles DA, Shenk T. 1992. Adenovirus L1 52- and 55-kilodalton proteins are present within assembling virions and colocalize with nuclear structures distinct from replication centers. J Virol 66:6133-6142.
32. Zhang W, Imperiale MJ. 2003. Requirement of the adenovirus IVa2 protein for virus assembly. J Virol 77:3586-3594.
33. Stewart PL, Fuller SD, Burnett RM. 1993. Difference imaging of adenovirus: Bridging the resolution gap between X-ray crystallography and electron microscopy. EMBO J 12:2589-2599.
34. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. 1997. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323.
35. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. 1993. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73:309-319.
36. Greber UF, Willetts M, Webster P, Helenius A. 1993. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75:477-486.
37. Greber UF, Webster P, Weber J, Helenius A. 1996. The role of the adenovirus protease on virus entry into cells. EMBO J 15:1766-1777.
38. Ruzindana-Umunyana A, Imbeault L, Weber JM. 2002. Substrate specificity of adenovirus protease. Virus Res 89:41-52.
39. Wiethoff CM, Wodrich H, Gerace L, Nemerow GR. 2005. Adenovirus Protein VI mediates membrane disruption following capsid disassembly. J Virol 79:1992-2000.
40. Berkowitz SA. 2006. Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals. AAPS J 8:E590-E605.